A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer

Trial Profile

A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Acalabrutinib (Primary) ; Pembrolizumab
  • Indications Ovarian cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms KEYNOTE191
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 27 Jun 2016 Planned End Date changed from 1 Aug 2018 to 1 Jul 2018.
    • 12 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 04 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top